Spain & India, working in the clinical development for a novel therapy against pediatric brain tumors

Gate2Brain

Gate2Brain has developed a disruptive technology aimed at enhancing drug delivery to the brain. The company focuses on creating innovative new drugs capable of crossing the blood-brain barrier (BBB), a highly impermeable structure that significantly hinders the transport of therapeutic agents to the central nervous system (CNS). Gate2Brain’s technology is based on a peptide-based shuttle platform that can transport a wide variety of therapeutic molecules across the BBB.

Advantages of Gate2Brain’s Peptide Technology

Gate2Brain’s proprietary peptides offer multiple advantages:

• Non-invasive and highly efficient solution
• High resistance to proteases
• Small size, leading to a cost-effective synthesis process
• Low risk of immunogenicity

 

G2B-002: A Novel Treatment for Pediatric Brain Tumors

Currently, the company is developing G2B-002, a drug specifically designed for the treatment of high-grade pediatric brain tumors. This candidate has already demonstrated:

• Anticancer activity in intracerebral animal models derived from patients diagnosed with brain tumors
• Ability to cross the BBB and effectively deliver the active therapeutic agent
• Good treatment tolerability in rodents

 

A Revolutionary Platform for CNS Drug Delivery

Gate2Brain offers a groundbreaking technology platform that represents an unprecedented advancement in the treatment of high-grade pediatric brain tumors, aiming to improve both prognosis and quality of life for patients. Moreover, this platform has great potential for enhancing drug delivery in a wide range of CNS-related diseases.

 

Advancing Towards Clinical Trials

Through this project, Gate2Brain aims to:

• Complete the regulatory preclinical development of its drug candidate
• Move towards the initiation of a Phase I/IIa clinical trial in patients diagnosed with diffuse midline glioma (DMG)

 

Strategic Collaborations for Success

This collaboration with key partners will enable the successful execution of all project activities, including analysis, manufacturing, and stability studies.

 

CDTI Multipaís Program

This project is part of CDTI’s Multipaís 2024 program, within the framework of the Recovery, Transformation, and Resilience Plan, which includes the strengthening and internationalization of industrial capacities in the health sector through multi-country R&D projects linked to the Vanguard Health PERTE (Strategic Project for Economic Recovery and Transformation).

The main objective of this program is to support projects within the scope of Vanguard Health, defined as the promotion and protection of health through the development and integration of innovative products, procedures, and digital solutions that enhance personalized prevention, diagnosis, treatment, or rehabilitation for patients.

This project is funded by the Centro para el Desarrollo Tecnológico Industrial (CDTI Innovación) and supported by the Ministry of Science and Innovation, the Recovery, Transformation, and Resilience Plan, and the European Union (NextGenerationEU).